FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360606241> ?p ?o ?g. }

• W4360606241 abstract "You have accessJournal of UrologyCME1 Apr 2023PD44-10 ASSOCIATION BETWEEN ANTIBIOTIC AND TREATMENT EFFICACY IN UROTHELIAL CARCINOMA PATIENTS RECEIVING IMMUNOTHERAPY OR CHEMOTHERAPY Avery Braun, Laura Bukavina, Mengying Deng, M. Math, Elizabeth Handorf, and Philip Abbosh Avery BraunAvery Braun More articles by this author , Laura BukavinaLaura Bukavina More articles by this author , Mengying DengMengying Deng More articles by this author , M. MathM. Math More articles by this author , Elizabeth HandorfElizabeth Handorf More articles by this author , and Philip AbboshPhilip Abbosh More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003354.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Research suggest ABT-induced dysbiosis impacts responses to immune checkpoint inhibitors (ICI) therapy. We investigated the association between ABT and overall survival (OS) and real-world progression free survival (rwPFS) in patients with metastatic urothelial carcinoma (mUC) receiving either ICI or non-ICI (cisplatin-based chemotherapy) as a reference group. METHODS: We included 5,622 patients with mUC from the nationwide Flatiron Health electronic health record -derived de-identified database (ICI N=1483; non-ICI N=4139). rwPFS and OS were calculated from treatment initiation to date of real-world progression/death. 3-month landmark Kaplan Meier methods and log-rank tests were used to estimate and compare rwPFS and OS between patients with ABT who received ICI and non-ICI. Cox proportional models were used to investigate the association between rwPFS, OS, and antibiotic use, and treatment modality, adjusting for patient characteristics. RESULTS: 407 (27.4%) ICI and 1523 (36.8%) non-ICI patients received ABT (p<0.001). ICI (OR 0.704, p<0.001) and older age (OR 0.979, p<0.001) were associated with lower ABT use in multivariable analysis. The association between ABT and rwPFS and OS were not significantly different between ICI (rwPFS p=0.43; OS p=0.07) and non-ICI groups (rwPFS p=0.60; OS p=0.99; Figure 1). Timing of ABT as associated with reduced OS in ICI-recipients who received post-treatment ABT (ICI median: pre- 17.0 vs post- 10.9 vs none- 16.0; p=0.005) while rwPFS was not statistically impacted by timing of antibiotic in either group (ICI p=0.22; non-ICI p=0.84; Figure 2) In multivariable analysis, ABT was associated with OS in the ICI cohort only (HR 1.228, p=0.022). CONCLUSIONS: This study identifies an ICI-specific potential negative effect of ABT on OS in patients with mUC. These results support continued investigation of the gut microbiome health on UC treatment efficacy and emphasize the importance of antibiotic stewardship. Source of Funding: DoD # (CA181178)Fox Core Grant # (P30 CA 006927) © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1128 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Avery Braun More articles by this author Laura Bukavina More articles by this author Mengying Deng More articles by this author M. Math More articles by this author Elizabeth Handorf More articles by this author Philip Abbosh More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4360606241 created "2023-03-24" @default.
• W4360606241 creator A5008460713 @default.
• W4360606241 creator A5009380541 @default.
• W4360606241 creator A5011122559 @default.
• W4360606241 creator A5020968811 @default.
• W4360606241 creator A5025874222 @default.
• W4360606241 creator A5082723562 @default.
• W4360606241 date "2023-04-01" @default.
• W4360606241 modified "2023-09-26" @default.
• W4360606241 title "PD44-10 ASSOCIATION BETWEEN ANTIBIOTIC AND TREATMENT EFFICACY IN UROTHELIAL CARCINOMA PATIENTS RECEIVING IMMUNOTHERAPY OR CHEMOTHERAPY" @default.
• W4360606241 doi "https://doi.org/10.1097/ju.0000000000003354.10" @default.
• W4360606241 hasPublicationYear "2023" @default.
• W4360606241 type Work @default.
• W4360606241 citedByCount "0" @default.
• W4360606241 crossrefType "journal-article" @default.
• W4360606241 hasAuthorship W4360606241A5008460713 @default.
• W4360606241 hasAuthorship W4360606241A5009380541 @default.
• W4360606241 hasAuthorship W4360606241A5011122559 @default.
• W4360606241 hasAuthorship W4360606241A5020968811 @default.
• W4360606241 hasAuthorship W4360606241A5025874222 @default.
• W4360606241 hasAuthorship W4360606241A5082723562 @default.
• W4360606241 hasConcept C121608353 @default.
• W4360606241 hasConcept C126322002 @default.
• W4360606241 hasConcept C143998085 @default.
• W4360606241 hasConcept C2776694085 @default.
• W4360606241 hasConcept C2777701055 @default.
• W4360606241 hasConcept C2778239845 @default.
• W4360606241 hasConcept C2780352672 @default.
• W4360606241 hasConcept C3019882237 @default.
• W4360606241 hasConcept C50382708 @default.
• W4360606241 hasConcept C71924100 @default.
• W4360606241 hasConceptScore W4360606241C121608353 @default.
• W4360606241 hasConceptScore W4360606241C126322002 @default.
• W4360606241 hasConceptScore W4360606241C143998085 @default.
• W4360606241 hasConceptScore W4360606241C2776694085 @default.
• W4360606241 hasConceptScore W4360606241C2777701055 @default.
• W4360606241 hasConceptScore W4360606241C2778239845 @default.
• W4360606241 hasConceptScore W4360606241C2780352672 @default.
• W4360606241 hasConceptScore W4360606241C3019882237 @default.
• W4360606241 hasConceptScore W4360606241C50382708 @default.
• W4360606241 hasConceptScore W4360606241C71924100 @default.
• W4360606241 hasIssue "Supplement 4" @default.
• W4360606241 hasLocation W43606062411 @default.
• W4360606241 hasOpenAccess W4360606241 @default.
• W4360606241 hasPrimaryLocation W43606062411 @default.
• W4360606241 hasRelatedWork W2085978374 @default.
• W4360606241 hasRelatedWork W2100029565 @default.
• W4360606241 hasRelatedWork W2374812810 @default.
• W4360606241 hasRelatedWork W2381460883 @default.
• W4360606241 hasRelatedWork W2414573978 @default.
• W4360606241 hasRelatedWork W2471989939 @default.
• W4360606241 hasRelatedWork W3100395499 @default.
• W4360606241 hasRelatedWork W363598932 @default.
• W4360606241 hasRelatedWork W4206600817 @default.
• W4360606241 hasRelatedWork W4243635653 @default.
• W4360606241 hasVolume "209" @default.
• W4360606241 isParatext "false" @default.
• W4360606241 isRetracted "false" @default.
• W4360606241 workType "article" @default.